SCHEMBL4297890

SCHEMBL4297890

COCCOc1ccc(F)c(F)c1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.38
HPGD P15428 2/20 0.38
HTR2C P28335 4/20 0.37
HTR2B P41595 3/20 0.37
HTR2A P28223 2/20 0.37
HTT P42858 2/20 0.37
KMT2A Q03164 1/20 0.37
RET P07949 1/20 0.36
KIF5B P33176 1/20 0.36
GRM2 Q14416 2/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
ALDH1A1 P00352 1/20 0.35
FLT1 P17948 3/20 0.34
KDR P35968 3/20 0.34
PLAU P00749 1/20 0.34
FGFR1 P11362 2/20 0.34
KCNN4 O15554 1/20 0.33
JAK2 O60674 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4303587 0.83 L3MBTL1 (0.37) KDM4EHPGDHTR2CHTR2BHTR2A
SCHEMBL27724756 0.80 L3MBTL1 (0.47) KDM4EHPGDKMT2AGRM2TDP1
SCHEMBL23723740 0.79 HTR2C (0.41) KDM4EHPGDHTR2CHTR2BHTR2A
SCHEMBL4300393 0.79 GNRHR (0.38) KDM4EHPGDHTR2CHTR2BHTR2A
SCHEMBL4305497 0.79 HTR2C (0.40) KDM4EHPGDHTR2CHTR2BHTR2A
SCHEMBL2929463 0.77 HTT (0.40) KDM4EHPGDHTTKMT2AGRM2
SCHEMBL4299690 0.77 HTR2A (0.35) HTR2CHTR2BHTR2AGRM2
SCHEMBL4302346 0.77 MAPK1 (0.46) KDM4EHPGDHTR2CHTR2BHTR2A
SCHEMBL22732575 0.76 JAK2 (0.38) KDM4EHPGDHTTKMT2ARET
SCHEMBL10300147 0.76 HTR2C (0.38) KDM4EHPGDHTR2CHTR2BHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1939204-B3 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF KISSEI PHARMACEUTICAL (JP) 2022-08-24 EP disclosed
US-9040693-B2 Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2015-05-26 US disclosed
US-9040693-B2 Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2015-05-26 US disclosed
US-9040693-B2 Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2015-05-26 US disclosed
EP-1939204-B1 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF KISSEI PHARMACEUTICAL (JP) 2013-01-02 EP disclosed
US-20090325900-A1 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
US-20090325900-A1 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
US-20090325900-A1 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-1939204-A1 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325900-A1 FUSED HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF SHBG, CYP19A1, NR5A1 KDM4E 930/4885HPGD 728/4885HTR2C 1435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.